Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $12.77 Consensus Target Price from Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has earned a consensus rating of “Buy” from the fourteen analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $12.7692.

A number of equities research analysts have recently issued reports on TSHA shares. Bank of America lifted their price target on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Wall Street Zen cut shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Wednesday, June 24th. The Goldman Sachs Group upped their price target on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Finally, Pivotal Research set a $14.00 price objective on Taysha Gene Therapies in a report on Tuesday, June 23rd.

Taysha Gene Therapies Trading Up 4.8%

Shares of TSHA stock opened at $5.88 on Friday. The business’s fifty day moving average price is $5.99 and its 200 day moving average price is $5.38. Taysha Gene Therapies has a 1-year low of $2.54 and a 1-year high of $7.30. The firm has a market capitalization of $1.69 billion, a PE ratio of -15.47 and a beta of 1.17. The company has a debt-to-equity ratio of 0.23, a current ratio of 14.04 and a quick ratio of 14.04.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Wednesday, May 6th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). As a group, sell-side analysts forecast that Taysha Gene Therapies will post -0.49 EPS for the current fiscal year.

Insider Activity at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $6.24, for a total value of $1,248,000.00. Following the completion of the sale, the insider owned 936,410 shares of the company’s stock, valued at $5,843,198.40. This represents a 17.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC boosted its holdings in Taysha Gene Therapies by 325.6% in the 1st quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock worth $150,000 after acquiring an additional 82,545 shares during the period. Rhumbline Advisers raised its stake in shares of Taysha Gene Therapies by 13.5% during the second quarter. Rhumbline Advisers now owns 233,256 shares of the company’s stock valued at $539,000 after purchasing an additional 27,794 shares during the period. Prudential Financial Inc. raised its stake in shares of Taysha Gene Therapies by 50.5% during the second quarter. Prudential Financial Inc. now owns 22,790 shares of the company’s stock valued at $53,000 after purchasing an additional 7,650 shares during the period. Invesco Ltd. lifted its position in shares of Taysha Gene Therapies by 27.4% during the second quarter. Invesco Ltd. now owns 203,671 shares of the company’s stock worth $470,000 after purchasing an additional 43,772 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Taysha Gene Therapies during the second quarter worth $184,000. 77.70% of the stock is owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.